SCHEMBL30714728

SCHEMBL30714728

Cc1ncsc1COc1ccc2nn(C)c(C(=O)NC3(C(N)=O)CCOCC3)c2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.34
MMP3 P08254 3/20 0.34
ADAM17 P78536 3/20 0.34
MMP7 P09237 2/20 0.34
ADAMTS4 O75173 1/20 0.34
ADAMTS1 Q9UHI8 1/20 0.34
ADAMTS5 Q9UNA0 1/20 0.34
MMP13 P45452 2/20 0.33
MMP2 P08253 1/20 0.33
MMP12 P39900 1/20 0.33
LRRK2 Q5S007 2/20 0.31
HPGD P15428 2/20 0.31
ALDH1A1 P00352 3/20 0.31
MMP1 P03956 1/20 0.31
CYP4F2 P78329 1/20 0.30
CYP4A11 Q02928 1/20 0.30
GAA P10253 2/20 0.30
SMN1; SMN2 Q16637 2/20 0.30
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714760 0.95 MMP3 (0.32) CNR2MMP3ADAM17MMP7ADAMTS4
SCHEMBL30714608 0.93 HPGD (0.32) MMP3ADAM17HPGD
SCHEMBL30714754 0.92 HPGD (0.32) MMP3ADAM17HPGD
SCHEMBL26874590 0.88 ADAM17 (0.39) CNR2MMP3ADAM17MMP7ADAMTS4
SCHEMBL31539872 0.84 HPGD (0.32) MMP3ADAM17MMP7ADAMTS4ADAMTS1
SCHEMBL30714700 0.84 ADAM17 (0.33) MMP3ADAM17MMP7ADAMTS4ADAMTS1
SCHEMBL30714653 0.83 SCN9A (0.36) MMP3ADAM17MMP7ADAMTS4ADAMTS1
SCHEMBL30714638 0.82 P2RY12 (0.39)
SCHEMBL31539893 0.82 HPGD (0.32) HPGD
SCHEMBL30714616 0.82 NPC1 (0.40) CNR2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 CNR2 107/4885MMP3 603/4885ADAM17 3090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.